-transparent.png){kind=logo}
Simultaneous hemodynamic and equilibrium radionuclide function measurements were performed at rest and during exercise before and 75 min after oral administration of 30 mg bufuralol, a nonselective beta-adrenoceptor blocking drug, in 10 patients with stable angina pectoris. Acute beta-blockade with bufuralol resulted in a reduction of exercise-stimulated heart rate, Systolic blood pressure, and cardiac index. There was, however, also a fall in diastolic blood pressure and end-diastolic volume index, and an improved global left ventricular ejection fraction, without a change in total vascular resistance, suggesting an acute vasodilator effect. regional analysis revealed that this beneficial effect was particularly present in ischemic segments of the left ventricular wall where regional function increased. Thus, bufuralol is a beta-adrenoceptor blocking agent with additional peripheral vasodilating properties.
M Pfisterer, and
D Burckhardt, and
F R Bühler, and
F Burkart
November 1975,
Experientia,
M Pfisterer, and
D Burckhardt, and
F R Bühler, and
F Burkart
November 1982,
European journal of pharmacology,
M Pfisterer, and
D Burckhardt, and
F R Bühler, and
F Burkart
December 1987,
European heart journal,
M Pfisterer, and
D Burckhardt, and
F R Bühler, and
F Burkart
July 1977,
Arzneimittel-Forschung,
M Pfisterer, and
D Burckhardt, and
F R Bühler, and
F Burkart
January 1984,
Journal of cardiovascular pharmacology,
M Pfisterer, and
D Burckhardt, and
F R Bühler, and
F Burkart
January 1982,
British journal of clinical pharmacology,
M Pfisterer, and
D Burckhardt, and
F R Bühler, and
F Burkart
October 1984,
Archives internationales de pharmacodynamie et de therapie,
M Pfisterer, and
D Burckhardt, and
F R Bühler, and
F Burkart
March 1991,
American heart journal,
M Pfisterer, and
D Burckhardt, and
F R Bühler, and
F Burkart
January 1983,
European journal of clinical pharmacology,
M Pfisterer, and
D Burckhardt, and
F R Bühler, and
F Burkart
September 1987,
Japanese heart journal,
